🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

The Purpose of This Clinical Study is to Evaluate Optimized Maximum Plus for Maximum Visual Acuity (MPMVA) Refractive Technique and Its Effect on Visual Performance.

Recruitingn/aAges 21 Years - anyAllHoya Surgical Optics, Inc.
NCT07595432 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

This is a prospective, multicenter, parallel groups, non-interventional, examiner masked, comparative clinical study. Patients that participated in previous Hoya studies, and patients previous implanted with Hoya non-toric monofocal IOLs (sub-study only) will be enrolled in the study. The sample size for this study is based on demonstrating the non-inferiority of the mean distance-corrected intermediate visual acuity (DCIVA) in Group 1 (Site 1) compared with Group 2 (Site 2).

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: Main study: 1. Previously implanted with intraocular lens through 2 previous IOL studies; 2. Clear intraocular media with no clinically significant opacity, in the investigator's judgment, that would affect visual acuity; 3. Able to provide informed consent and complete all required study procedures. Exploratory sub-study: 1\. Additional inclusion criteria: Pseudophakic eyes implanted with one of the IOLs in one eye from 3 previous IOL studies Exclusion Criteria: Main study: 1. Corrected distance visual acuity (CDVA) worse than 0.2 logMAR (or 20/32 Snellen) 2. Subjects with ongoing medical conditions or treatment that might impact outcomes during the study visit as determined by the investigator. Exploratory sub-study: 1\. Additional exclusion criteria: Pseudophakic eyes with oblique residual astigmatism.
💊

What it tests

  • Non-Interventional Study
📍

Where

1 site
Peregrine Eye Laser Institute
Manila, Philippines
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy